Mayumi Ueta

List of Publications by Year
in descending order

145 papers	4,913 citations	117625 34 h-index	110387 64 g-index
145 all docs	145 docs citations	145 times ranked	3276 citing authors

#	Article	IF	Citations
1	Association of HLA polymorphisms and acetaminophen-related Steven-Johnson syndrome with severe ocular complications in Thai population. British Journal of Ophthalmology, 2022, 106, 884-888.	3.9	7
2	Human leucocyte antigen association of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications in Han Chinese. British Journal of Ophthalmology, 2022, 106, 610-615.	3.9	24
3	Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases. British Journal of Ophthalmology, 2022, 106, 1355-1362.	3.9	10
4	Challenges in the management of bilateral eyelid closure in Stevens-Johnson Syndrome. American Journal of Ophthalmology Case Reports, 2022, 26, 101473.	0.7	2
5	Limbal-Rigid Contact Lens Wear for the Treatment of Ocular Surface Disorders: A Review. Eye and Contact Lens, 2022, 48, 313-317.	1.6	3
6	Topical application of toll-like receptor 3 inhibitors ameliorates chronic allergic skin inflammation in mice. Journal of Dermatological Science, 2021, 101, 141-144.	1.9	3
7	Human leukocyte antigen B*0702 is protective against ocular Stevensâ€“Johnson syndrome/toxic epidermal necrolysis in the UK population. Scientific Reports, 2021, 11, 2928.	3.3	5
8	Mapping of susceptible variants for cold medicine-related Stevensâ€“Johnson syndrome by whole-genome resequencing. Npj Genomic Medicine, 2021, 6, 9.	3.8	3
9	Regional heritability mapping identifies several novel loci (STAT4, ULK4, and KCNH5) for primary biliary cholangitis in the Japanese population. European Journal of Human Genetics, 2021, 29, 1282-1291.	2.8	6
10	Human leukocyte antigen class I and II genes associated with dipyrone-related Stevens-Johnson syndrome and severe ocular complications in a Brazilian population. Ocular Surface, 2021, 20, 173-175.	4.4	4
11	Regulation of innate immune response by miR-628â€“3p upregulated in the plasma of Stevens-Johnson syndrome patients. Ocular Surface, 2021, 21, 174-177.	4.4	4
12	Japan: Diagnosis and Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications. Frontiers in Medicine, 2021, 8, 657327.	2.6	5
13	Difference in the plasma level of miRâ€628â€3p in atopic dermatitis patients with/without atopic keratoconjunctivitis. Immunity, Inflammation and Disease, 2021, 9, 1815-1819.	2.7	7
14	Corticosteroid Pulse Therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Patients With Acute Ocular Involvement. American Journal of Ophthalmology, 2021, 231, 194-199.	3.3	6
15	Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications. Frontiers in Medicine, 2021, 8, 651247.	2.6	9
16	Categorization of the Ocular Microbiome in Japanese Stevensâ€“Johnson Syndrome Patients With Severe Ocular Complications. Frontiers in Cellular and Infection Microbiology, 2021, 11, 741654.	3.9	3
17	Findings by an International Collaboration on SJS/TEN With Severe Ocular Complications. Frontiers in Medicine, 2021, 8, 649661.	2.6	5
18	Multi-state model for predicting ocular progression in acute Stevens-Johnson syndrome/toxic epidermal necrolysis. PLoS ONE, 2021, 16, e0260730.	2.5	3

#	Article	IF	Citations
19	Editorial: The Updated Understanding of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Frontiers in Medicine, 2021, 8, 811570.	2.6	1
20	Expression of prostaglandin E2 receptor 3 in the eyelid epidermis of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. British Journal of Ophthalmology, 2020, 104, 1022-1027.	3.9	6
21	HLA genotypes and cold medicine-induced Stevensâ€“Johnson syndrome/toxic epidermal necrolysis with severe ocular complications: a systematic review and meta-analysis. Scientific Reports, 2020, 10, 10589.	3.3	12
22	The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018. Journal of Dermatological Science, 2020, 100, 175-182.	1.9	31
23	Predictive biomarkers for the progression of ocular complications in chronic Stevens-Johnson syndrome and toxic Eeidermal necrolysis. Scientific Reports, 2020, 10, 18922.	3.3	14
24	Regulation of gene expression by miRNA-455-3p, upregulated in the conjunctival epithelium of patients with Stevensâ€“Johnson syndrome in the chronic stage. Scientific Reports, 2020, 10, 17239.	3.3	7
25	Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis. Allergology International, 2020, 69, 465-467.	3.3	3
26	Clinical trial to evaluate the therapeutic benefits of limbal-supported contact lens wear for ocular sequelae due to Stevens-Johnson syndrome/toxic epidermal necrolysis. Contact Lens and Anterior Eye, 2020, 43, 535-542.	1.7	9
27	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.9	41
28	Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications. Expert Review of Clinical Immunology, 2020, 16, 285-291.	3.0	15
29	Long-term Progression of Ocular Surface Disease in Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis. Cornea, 2020, 39, 745-753.	1.7	17
30	Oral Mucosal Epithelial Transplantation and Limbal-Rigid Contact Lens: A Therapeutic Modality for the Treatment of Severe Ocular Surface Disorders. Cornea, 2020, 39, S19-S27.	1.7	6
31	Gene expression analysis of conjunctival epithelium of patients with Stevens-Johnson syndrome in the chronic stage. BMJ Open Ophthalmology, 2019, 4, e000254.	1.6	5
32	Association of HLA class I and II gene polymorphisms with acetaminophen-related Stevensâ€“Johnson syndrome with severe ocular complications in Japanese individuals. Human Genome Variation, 2019, 6, 50.	0.7	17
33	Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing. Scientific Reports, 2019, 9, 16240.	3.3	16
34	Stratum corneum Toll-like receptor 3 expressions correlate with the severity of atopic dermatitis lesions. Journal of Dermatological Science, 2019, 94, 354-357.	1.9	8
35	Stevensâ€Johnson syndrome and toxic epidermal necrolysis cases treated at our hospital over the past 10Âyears. Journal of Cutaneous Immunology and Allergy, 2019, 2, 25-30.	0.3	3
36	Association of human antigen class I genes with cold medicine-related Stevens-Johnson syndrome with severe ocular complications in a Korean population. British Journal of Ophthalmology, 2019, 103, 573-576.	3.9	18

#	Article	IF	Citations
37	Characteristics of meibomian gland dysfunction in patients with Stevensâ€“Johnson syndrome. Medicine (United States), 2019, 98, e16155.	1.0	12
38	Association of IKZF1 SNPs in cold medicine-related Stevensâ€“Johnson syndrome in Thailand. Clinical and Translational Allergy, 2019, 9, 61.	3.2	5
39	Distinctly regulated functions and mobilization of CD11c-positive cells elicited by TLR3- and IPS-1 signaling in the cornea. Immunology Letters, 2019, 206, 49-53.	2.5	3
40	<scp>HLA</scp> Alleles and <scp>CYP</scp>2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians. Clinical Pharmacology and Therapeutics, 2019, 105, 476-485.	4.7	53
41	Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevensâ€“Johnson syndrome. International Ophthalmology, 2019, 39, 55-62.	1.4	10
42	Influence of topical steroids on intraocular pressure in patients with atopic dermatitis. Allergology International, 2018, 67, 388-391.	3.3	10
43	A new dry eye mouse model produced by exorbital and intraorbital lacrimal gland excision. Scientific Reports, 2018, 8, 1483.	3.3	43
44	Association between HLA-B*44:03-HLA-C*07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand. British Journal of Ophthalmology, 2018, 102, 1303-1307.	3.9	30
45	Chronic ocular complications of Stevens-Johnson syndrome associated with causative medications in Korea. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 700-702.e2.	3.8	10
46	Mucocutaneous inflammation in the Ikaros Family Zinc Finger 1â€keratin 5â€“specific transgenic mice. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 395-404.	5.7	12
47	Results of Detailed Investigations Into Stevens-Johnson Syndrome With Severe Ocular Complications. , 2018, 59, DES183.		27
48	Severe Dry Eye With Combined Mechanisms is Involved in the Ocular Sequelae of SJS/TEN at the Chronic Stage. , 2018, 59, DES80.		32
49	Diagnostic efficacy of real-time PCR for ocular cytomegalovirus infections. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 2413-2420.	1.9	30
50	Diagnostic efficacy of real-time PCR for ocular cytomegalovirus infections. , 2018, 256, 2413.		1
51	Human Leukocyte Antigen Class I Genes Associated With Stevens-Johnson Syndrome and Severe Ocular Complications Following Use of Cold Medicine in a Brazilian Population. JAMA Ophthalmology, 2017, 135, 355.	2.5	29
52	The effect of topical application of 0.15% ganciclovir gel on cytomegalovirus corneal endotheliitis. British Journal of Ophthalmology, 2017, 101, 114-119.	3.9	38
53	Genome-wide association study using the ethnicity-specific Japonica array: identification of new susceptibility loci for cold medicine-related Stevensâ€“Johnson syndrome with severe ocular complications. Journal of Human Genetics, 2017, 62, 485-489.	2.3	18
54	The role of toll-like receptor 3 in chronic contact hypersensitivity induced by repeated elicitation. Journal of Dermatological Science, 2017, 88, 184-191.	1.9	18

#	Article	IF	Citations
55	Data Sparsity in Study on Human Leukocyte Antigen Class I Genes Associated With Stevens-Johnson Syndrome and Severe Ocular Complicationsâ€"Reply. JAMA Ophthalmology, 2017, 135, 894.	2.5	0
56	Association of Human Leukocyte Antigen Class 1 genes with Stevens Johnson Syndrome with severe ocular complications in an Indian population. Scientific Reports, 2017, 7, 15960.	3.3	15
57	Reply: amniotic membrane transplantation in Stevens-Johnson syndrome. Survey of Ophthalmology, 2017, 62, 249-250.	4.0	0
58	Downregulation of interferon-Î³-induced protein 10 in the tears of patients with Stevens-Johnson syndrome with severe ocular complications in the chronic stage. BMJ Open Ophthalmology, 2017, 1, e000073.	1.6	17
59	Visualization of Intravital Immune Cell Dynamics After Conjunctival Surgery Using Multiphoton Microscopy. , 2016, 57, 1207.		6
60	Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis â€" A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease. Ocular Surface, 2016, 14, 168-188.	4.4	163
61	Cold medicine-related Stevensâ€"Johnson syndrome/toxic epidermal necrolysis with severe ocular complicationsâ€"phenotypes and genetic predispositions. Taiwan Journal of Ophthalmology, 2016, 6, 108-118.	0.7	10
62	TLR3 and Inflammatory Skin Diseases: From Environmental Factors to Molecular Opportunities. , 2016, , 235-249.		1
63	Intravital imaging of the cellular dynamics of LysM-positive cells in a murine corneal suture model. British Journal of Ophthalmology, 2016, 100, 432-435.	3.9	7
64	Analysis of Ocular Manifestation and Genetic Association of Allopurinol-Induced Stevensâ€"Johnson Syndrome and Toxic Epidermal Necrolysis in South Korea. Cornea, 2016, 35, 199-204.	1.7	17
65	Stevens-Johnson syndrome: The role of an ophthalmologist. Survey of Ophthalmology, 2016, 61, 369-399.	4.0	65
66	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis â€" A Comprehensive Review and Guide to Therapy. I. Systemic Disease. Ocular Surface, 2016, 14, 2-19.	4.4	112
67	Plasma Lipid Profiling of Patients with Chronic Ocular Complications Caused by Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. PLoS ONE, 2016, 11, e0167402.	2.5	5
68	Novel TACSTD2 mutation in gelatinous drop-like corneal dystrophy. Human Genome Variation, 2015, 2, 15047.	0.7	3
69	HLA-A*02:06 and PTGER3 polymorphism exert additive effects in cold medicine-related Stevensâ€"Johnson syndrome with severe ocular complications. Human Genome Variation, 2015, 2, 15023.	0.7	19
70	Drugs causing severe ocular surface involvements in Japanese patients with Stevensâ€"Johnson syndrome/toxic epidermal necrolysis. Allergology International, 2015, 64, 379-381.	3.3	15
71	Genetic Predisposition to Stevensâ€"Johnson Syndrome With Severe Ocular Surface Complications. Cornea, 2015, 34, S158-S165.	1.7	21
72	Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. American Journal of Ophthalmology, 2015, 160, 228-237.e2.	3.3	104

#	Article	IF	Citations
73	The Role of Systemic Immunomodulatory Treatment and Prognostic Factors on Chronic Ocular Complications in Stevensâ€“Johnson Syndrome. Ophthalmology, 2015, 122, 254-264.	5.2	48
74	IKZF1, a new susceptibility gene for cold medicineâ€“related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. Journal of Allergy and Clinical Immunology, 2015, 135, 1538-1545.e17.	2.9	55
75	Development of a simple genotyping method for the HLA-A*31:01-tagging SNP in Japanese. Pharmacogenomics, 2015, 16, 1689-1699.	1.3	9
76	Toll-Like Receptor 3 Increases Allergic and Irritant Contact Dermatitis. Journal of Investigative Dermatology, 2015, 135, 411-417.	0.7	33
77	HLA-A*02:06 and PTGER3 polymorphism exerts additive effects in cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Japanese and Korean populations. Acta Ophthalmologica, 2015, 93, n/a-n/a.	1.1	0
78	Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity. Acta Ophthalmologica, 2014, 92, e447-53.	1.1	79
79	Downregulation of ILâ€8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops. Clinical and Translational Allergy, 2014, 4, 40.	3.2	7
80	Upregulation of Toll-like receptor 5 expression in the conjunctival epithelium of various human ocular surface diseases. British Journal of Ophthalmology, 2014, 98, 1116-1119.	3.9	8
81	Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments. Allergology International, 2014, 63, 75-81.	3.3	15
82	Medication tendencies for inducing severe ocular surface symptoms in Japanese Stevensâ€Johnson Syndrome / toxic epidermal necrolysis patients. Clinical and Translational Allergy, 2014, 4, P88.	3.2	0
83	HLA association with antipyretic analgesicsâ€induced Stevensâ€Johnson Syndrome/toxic epidermal necrolysis with severe ocular surface complications in japanese patients. Clinical and Translational Allergy, 2014, 4, P89.	3.2	1
84	Suppression of polyI:C-inducible gene expression by EP3 in murine conjunctival epithelium. Immunology Letters, 2014, 159, 73-75.	2.5	1
85	Folliculitis in Clinically â€œQuietâ€•Chronic Stevens-Johnson Syndrome. Ophthalmic Plastic and Reconstructive Surgery, 2014, 30, 80-82.	0.8	4
86	Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications. Scientific Reports, 2014, 4, 5981.	3.3	59
87	Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. Scientific Reports, 2014, 4, 4862.	3.3	83
88	Antiâ€inflammatory effect of rebamipide on the ocular surface. Clinical and Translational Allergy, 2013, 3, P21.	3.2	1
89	Visual Improvement after Cultivated Oral Mucosal Epithelial Transplantation. Ophthalmology, 2013, 120, 193-200.	5.2	126
90	Specific HLA types are associated with antiepileptic drug-induced Stevensâ€“Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics, 2013, 14, 1821-1831.	1.3	60

#	Article	IF	Citations
91	A whole-genome association study of major determinants for allopurinol-related Stevensâ€“Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics Journal, 2013, 13, 60-69.	2.0	160
92	Rebamipide Suppresses PolyI:C-Stimulated Cytokine Production in Human Conjunctival Epithelial Cells. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 688-693.	1.4	32
93	In SilicoRisk Assessment of HLA-A*02:06-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Caused by Cold Medicine Ingredients. Journal of Toxicology, 2013, 2013, 1-6.	3.0	12
94	Genetic susceptibility for Stevens-Johnson syndrome/Toxic epidermal necrolysis with mucosal involvements. Inflammation and Regeneration, 2013, 33, 249-260.	3.7	0
95	Expression of prostaglandin E receptor subtype EP4 in conjunctival epithelium of patients with ocular surface disorders: case-control study. BMJ Open, 2012, 2, e001330.	1.9	3
96	Epistatic Interactions Associated with Stevensâ€“Johnson Syndrome. Cornea, 2012, 31, S57-S62.	1.7	4
97	Downregulation of Monocyte Chemoattractant Protein 1 Expression by Prostaglandin E₂ in Human Ocular Surface Epithelium. JAMA Ophthalmology, 2012, 130, 249.	2.4	8
98	Prostaglandin E2 Suppresses Poly I. Cornea, 2012, 31, 1294-1298.	1.7	12
99	Epistatic interaction between Toll-like receptor 3 (TLR3) and prostaglandin E receptor 3 (PTGER3) genes. Journal of Allergy and Clinical Immunology, 2012, 129, 1413-1416.e11.	2.9	28
100	Ocular surface inflammation is regulated by innate immunity. Progress in Retinal and Eye Research, 2012, 31, 551-575.	15.5	80
101	HLA-A*0206 with TLR3 Polymorphisms Exerts More than Additive Effects in Stevens-Johnson Syndrome with Severe Ocular Surface Complications. PLoS ONE, 2012, 7, e43650.	2.5	32
102	Contribution of IPS-1 to polyI:C-induced cytokine production in conjunctival epithelial cells. Biochemical and Biophysical Research Communications, 2011, 404, 419-423.	2.1	19
103	Prostaglandin E Receptor Subtype EP3 Expression in Human Conjunctival Epithelium and Its Changes in Various Ocular Surface Disorders. PLoS ONE, 2011, 6, e25209.	2.5	30
104	Expression of interleukin-4 receptor Î± in human corneal epithelial cells. Japanese Journal of Ophthalmology, 2011, 55, 405-410.	1.9	17
105	Prostaglandin E2 suppresses polyinosine-polycytidylic acid (polyI:C)-stimulated cytokine production via prostaglandin E2 receptor (EP) 2 and 3 in human conjunctival epithelial cells. British Journal of Ophthalmology, 2011, 95, 859-863.	3.9	22
106	Prostaglandin E receptor subtype EP3 downregulates TSLP expression in human conjunctival epithelium. British Journal of Ophthalmology, 2011, 95, 742-743.	3.9	12
107	Cytokine storm arising on the ocular surface in a patient with Stevens-Johnson syndrome. British Journal of Ophthalmology, 2011, 95, 1030-1031.	3.9	20
108	Ocular Surface Inflammation Mediated by Innate Immunity. Eye and Contact Lens, 2010, 36, 269-281.	1.6	36

#	Article	IF	Citations
109	Regulation of Ocular Surface Inflammation by Prostaglandin E Receptor Subtype EP3. Cornea, 2010, 29, S57-S61.	1.7	8
110	Prostaglandin E Receptor 4 Expression in Human Conjunctival Epithelium and Its Downregulation in Devastating Ocular Surface Inflammatory Disorders. JAMA Ophthalmology, 2010, 128, 1369.	2.4	4
111	Innate immunity of the ocular surface. Japanese Journal of Ophthalmology, 2010, 54, 194-198.	1.9	3
112	Spatio-temporal dual effects of IÎºBÎ¶ dictates the caution on visual disturbance resulting from IÎºBÎ¶ deficiency. Immunology Letters, 2010, 133, 115.	2.5	1
113	HLAâ€B*1511 is a risk factor for carbamazepineâ€induced Stevensâ€Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia, 2010, 51, 2461-2465.	5.1	217
114	Expression of the interleukin-4 receptor Â in human conjunctival epithelial cells. British Journal of Ophthalmology, 2010, 94, 1239-1243.	3.9	24
115	Gene-expression analysis of polyI:C-stimulated primary human conjunctival epithelial cells. British Journal of Ophthalmology, 2010, 94, 1528-1532.	3.9	28
116	Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. Journal of Allergy and Clinical Immunology, 2010, 126, 1218-1225.e10.	2.9	59
117	Innate immunity of the ocular surface. Brain Research Bulletin, 2010, 81, 219-228.	3.0	96
118	The Management of Severe Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Archives of Dermatology, 2009, 145, 1336.	1.4	6
119	Identification of a novel HLAâ€B allele, HLAâ€B*5904. Tissue Antigens, 2009, 73, 612-614.	1.0	5
120	Diagnosis and Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Ocular Complications. Ophthalmology, 2009, 116, 685-690.	5.2	144
121	Successful Treatment of Stevens-Johnson Syndrome with Steroid Pulse Therapy at Disease Onset. American Journal of Ophthalmology, 2009, 147, 1004-1011.e1.	3.3	133
122	Prostaglandin E receptor subtype EP3 in conjunctival epithelium regulates late-phase reaction of experimental allergic conjunctivitis. Journal of Allergy and Clinical Immunology, 2009, 123, 466-471.e5.	2.9	55
123	Toll-like receptor 3 enhances late-phase reaction of experimental allergic conjunctivitis. Journal of Allergy and Clinical Immunology, 2009, 123, 1187-1189.e2.	2.9	36
124	Prostaglandin E2â€“EP3 signaling suppresses skin inflammation in murine contact hypersensitivity. Journal of Allergy and Clinical Immunology, 2009, 124, 809-818.e2.	2.9	83
125	Examination of Staphylococcus aureus on the Ocular Surface of Patients With Catarrhal Ulcers. Cornea, 2009, 28, 780-782.	1.7	10
126	Ethnic Differences in the Association Between Human Leukocyte Antigen and Stevens-Johnson Syndrome. European Ophthalmic Review, 2009, 03, 15.	0.3	6

#	Article	IF	Citations
127	Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome. British Journal of Ophthalmology, 2008, 92, 989-991.	3.9	46
128	HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevensâ€“Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics, 2008, 9, 1617-1622.	1.3	368
129	Human conjunctival epithelial cells express functional Toll-like receptor 5. British Journal of Ophthalmology, 2008, 92, 411-416.	3.9	29
130	Innate Immunity of the Ocular Surface and Ocular Surface Inflammatory Disorders. Cornea, 2008, 27, S31-S40.	1.7	51
131	Stat6-Independent Tissue Inflammation Occurs Selectively on the Ocular Surface and Perioral Skin of IÎºBÎ¶^{â^’/â^’}Mice. , 2008, 49, 3387.		18
132	Association of Combined IL-13/IL-4R Signaling Pathway Gene Polymorphism with Stevens-Johnson Syndrome Accompanied by Ocular Surface Complications. , 2008, 49, 1809.		47
133	HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Molecular Vision, 2008, 14, 550-5.	1.1	47
134	Polyclonality of Staphylococcus epidermidis residing on the healthy ocular surface. Journal of Medical Microbiology, 2007, 56, 77-82.	1.8	32
135	New Grading System for the Evaluation of Chronic Ocular Manifestations in Patients with Stevensâ€“Johnson Syndrome. Ophthalmology, 2007, 114, 1294-1302.	5.2	241
136	Strong Association Between HLA-A*0206 and Stevens-Johnson Syndrome in the Japanese. American Journal of Ophthalmology, 2007, 143, 367-368.	3.3	74
137	Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. British Journal of Ophthalmology, 2007, 91, 962-965.	3.9	99
138	Development of eosinophilic conjunctival inflammation at late-phase reaction in mast cellâ€“deficient mice. Journal of Allergy and Clinical Immunology, 2007, 120, 476-478.	2.9	13
139	Association of IL4R polymorphisms with Stevens-Johnson syndrome. Journal of Allergy and Clinical Immunology, 2007, 120, 1457-1459.	2.9	48
140	Human corneal epithelial cells respond to ocular-pathogenic, but not to nonpathogenic-flagellin. Biochemical and Biophysical Research Communications, 2006, 347, 238-247.	2.1	23
141	Spontaneous Ocular Surface Inflammation and Goblet Cell Disappearance in IÎºBÎ¶ Gene-Disrupted Mice. , 2005, 46, 579.		52
142	Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochemical and Biophysical Research Communications, 2005, 331, 285-294.	2.1	138
143	Intracellularly Expressed TLR2s and TLR4s Contribution to an Immunosilent Environment at the Ocular Mucosal Epithelium. Journal of Immunology, 2004, 173, 3337-3347.	0.8	143
144	Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction. Clinical and Experimental Immunology, 2002, 129, 464-470.	2.6	109

#	Article	IF	Citations
145	Susceptibility Genes and HLA for Cold Medicine-Related SJS/TEN with SOC. Frontiers in Genetics, 0, 13, .	2.3	2